Modulation Therapeutics Joins the Tampa Bay Technology Incubator

January 9, 2012
Tampa, Fl

USF CONNECT would like to welcome its newest company, Modulation Therapeutics, to the Tampa Bay Technology Incubator (TBTI). The company was founded in 2011 by University of South Florida faculty members and Moffitt Cancer Center researchers, Dr. Lori Hazlehurst (Associate Member of Molecular Oncology) and Dr. Mark McLaughlin (Senior Member, Drug Discovery Department). The company has recently been awarded a $90,000 James & Esther King TTCP grant and has an SBIR Phase I grant that is pending.

About Modulation Therapeutics

Modulation Therapeutics is an early stage biotech company dedicated to the cost-effective advancement of first in class molecules to improve patient outcomes in unmet medical needs such as relapsed multiple myeloma and AML two hematopoietic tumors characterized by homing to the bone marrow and solid tumors that metastasize to the bone including lung, breast and prostate.

About USF CONNECT and the TBTD

USF CONNECT focuses on the needs of Tampa Bay's technology and bio/life sciences entrepreneurs throughout the business life cycle. We provide the facilities, partners and resources for successful business development. We offer access to technologies, workforce programs, technology commercialization, critical research equipment, and incubator facilities. USF CONNECT adds value and delivers targeted, high level expertise when your business needs it most.

The Tampa Bay Technology Incubator (TBTI) is one vehicle through which USF CONNECT grows successful companies. TBTI supports technology research as a catalyst for economic development and advocates the creation and development of facilities for high-technology companies and related support functions.

Tracey Swartz
Communications & Marketing Officer
USF CONNECT
813.974.1082
http://www3.research.usf.edu/td/usf-connect.asp
taswartz@usf.edu